Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Markets & Finance

Pacific Growth Keeps 'Overweight' on Dyax

Pacific Growth reiterates its over-weight rating on Dyax (DYAX).

Analyst Thomas Dietz says Genzyme exercised an option to buy 50% of Dyax's DX-88, a treatment for a rare, inherited blood disorder called hereditary angioedema that causes uncontrolled swelling. He notes Genzyme will market this product globally in a hereditary angioedema setting. Dyax will receive undisclosed regulatory milestone payments and 50% of profits.

The next events for DX-88: A placebo-controlled, 48-patient Phase I/II trial referred to as EDEMA1, and a PhaseI/II trial to prevent blood loss and inflammation in patients undergoing coronary artery bypass graft surgery. Both studies are due by year-end 2003.

Dietz says he still finds Dyax attractive, and recommends starting or adding to positions ahead of the announcement of data from the ongoing EDEMA1 study, and the potential news of phage display antibody discovery partnerships in the second half of the year.

blog comments powered by Disqus